Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insmed (INSM) Cash & Equivalents (2016 - 2026)

Insmed's Cash & Equivalents history spans 17 years, with the latest figure at $582.2 million for Q1 2026.

  • Quarterly Cash & Equivalents rose 44.38% to $582.2 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $582.2 million through Mar 2026, up 44.38% year-over-year, with the annual reading at $510.4 million for FY2025, 8.03% down from the prior year.
  • Cash & Equivalents came in at $582.2 million for Q1 2026, up from $510.4 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $1.3 billion in Q2 2025 to a low of $334.8 million in Q3 2025.
  • The 5-year median for Cash & Equivalents is $515.7 million (2022), against an average of $643.9 million.
  • Year-over-year, Cash & Equivalents plummeted 55.18% in 2022 and then soared 103.43% in 2024.
  • Insmed's Cash & Equivalents stood at $1.1 billion in 2022, then plummeted by 55.09% to $482.4 million in 2023, then increased by 15.06% to $555.0 million in 2024, then fell by 8.03% to $510.4 million in 2025, then rose by 14.06% to $582.2 million in 2026.
  • Per Business Quant, the three most recent readings for INSM's Cash & Equivalents are $582.2 million (Q1 2026), $510.4 million (Q4 2025), and $334.8 million (Q3 2025).